These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34817416)

  • 1. Pharmacokinetics of Cefepime in Children on Extracorporeal Membrane Oxygenation: External Model Validation, Model Improvement and Dose Optimization.
    Thibault C; Moorthy GS; Vedar C; Naim MY; DiLiberto MA; Zuppa AF
    Pediatr Infect Dis J; 2022 Mar; 41(3):217-223. PubMed ID: 34817416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Population Pharmacokinetic Analysis to Study the Effect of Extracorporeal Membrane Oxygenation on Cefepime Disposition in Children.
    Zuppa AF; Zane NR; Moorthy G; Dalton HJ; Abraham A; Reeder RW; Carcillo JA; Yates AR; Meert KL; Berg RA; Sapru A; Mourani P; Notterman DA; Dean JM; Gastonguay MR;
    Pediatr Crit Care Med; 2019 Jan; 20(1):62-70. PubMed ID: 30431557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of cefepime in critically ill patients receiving extracorporeal membrane oxygenation (an ASAP ECMO study).
    Cheng V; Abdul-Aziz MH; Burrows F; Buscher H; Corley A; Diehl A; Jakob SM; Levkovich BJ; Pellegrino V; Que YA; Reynolds C; Rudham S; Wallis SC; Welch SA; Zacharias D; Roberts JA; Shekar K; Fraser JF
    Int J Antimicrob Agents; 2021 Dec; 58(6):106466. PubMed ID: 34688834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and Time above the MIC Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO).
    Kois AK; Gluck JA; Nicolau DP; Kuti JL
    Int J Antimicrob Agents; 2022 Jul; 60(1):106603. PubMed ID: 35577257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and Pharmacodynamics of Extended-Infusion Cefepime in Critically Ill Patients Receiving Continuous Renal Replacement Therapy: A Prospective, Open-Label Study.
    Philpott CD; Droege CA; Droege ME; Healy DP; Courter JD; Ernst NE; Harger NJ; Foertsch MJ; Winter JB; Carter KE; Van Fleet SL; Athota K; Mueller EW
    Pharmacotherapy; 2019 Nov; 39(11):1066-1076. PubMed ID: 31549737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy.
    Hahn J; Min KL; Kang S; Yang S; Park MS; Wi J; Chang MJ
    Microbiol Spectr; 2021 Dec; 9(3):e0063321. PubMed ID: 34937189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefepime pharmacokinetics in adult extracorporeal membrane oxygenation patients.
    Zheng L; Alshaer MH; Peloquin C; Venugopalan V; Alnuaimat HM; Converse M
    Pulm Pharmacol Ther; 2024 Mar; 84():102271. PubMed ID: 38008397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The population pharmacokinetics and dose optimization of polymyxin B in critically ill patients with or without extracorporeal membrane oxygenation.
    Ye Q; Wang Q; Chen W; Zhang R; Chen Z; Li P; Zhang X; Zhan Q; Wang C
    J Clin Pharm Ther; 2022 Oct; 47(10):1608-1618. PubMed ID: 35716048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Randomized Pharmacokinetic and Pharmacodynamic Evaluation of Every 8-Hour and 12-Hour Dosing Strategies of Vancomycin and Cefepime in Neurocritically ill Patients.
    Kassel LE; Van Matre ET; Foster CJ; Fish DN; Mueller SW; Sherman DS; Wempe MF; MacLaren R; Neumann RT; Kiser TH
    Pharmacotherapy; 2018 Sep; 38(9):921-934. PubMed ID: 29906310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adequacy of cefepime concentrations in the early phase of critical illness: A case for precision pharmacotherapy.
    Barreto EF; Chang J; Bjergum MW; Gajic O; Jannetto PJ; Mara KC; Meade LA; Rule AD; Vollmer KJ; Scheetz MH;
    Pharmacotherapy; 2023 Nov; 43(11):1112-1120. PubMed ID: 36648390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cefepime Precision Dosing Tool: from Standard to Precise Dose Using Nonparametric Population Pharmacokinetics.
    Alshaer MH; Goutelle S; Santevecchi BA; Shoulders BR; Venugopalan V; Cherabuddi K; Liu J; Kiel PJ; Roberts JA; Sime FB; Scheetz MH; Neely MN; Peloquin CA
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0204621. PubMed ID: 34902271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Target Attainment of Cefepime in Critically Ill Patients and Guidance for Initial Dosing.
    Al-Shaer MH; Neely MN; Liu J; Cherabuddi K; Venugopalan V; Rhodes NJ; Klinker K; Scheetz MH; Peloquin CA
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32601155
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.
    de Cacqueray N; Hirt D; Zheng Y; Bille E; Leger PL; Rambaud J; Toubiana J; Chosidow A; Vimont S; Callot D; Chouchana L; Béranger A; Tréluyer JM; Benaboud S; Oualha M
    Clin Microbiol Infect; 2022 Oct; 28(10):1389.e1-1389.e7. PubMed ID: 35605841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefepime pharmacokinetics in critically ill children and young adults undergoing continuous kidney replacement therapy.
    Pavia K; Hambrick HR; Paice K; Tang P; Punt N; Kaplan J; Goldstein SL; Vinks AA; Mizuno T; Tang Girdwood S
    J Antimicrob Chemother; 2023 Sep; 78(9):2140-2147. PubMed ID: 37466170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic model of cefepime for critically ill adults: a comparative assessment of eGFR equations.
    Barreto EF; Chang J; Rule AD; Mara KC; Meade LA; Paul J; Jannetto PJ; Athreya AP; Scheetz MH;
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0081023. PubMed ID: 37882514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of intravenous sufentanil in critically ill patients supported with extracorporeal membrane oxygenation therapy.
    Hahn J; Yang S; Min KL; Kim D; Jin BH; Park C; Park MS; Wi J; Chang MJ
    Crit Care; 2019 Jul; 23(1):248. PubMed ID: 31288863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetic Assessment and Pharmacodynamic Implications of Pediatric Cefepime Dosing for Susceptible-Dose-Dependent Organisms.
    Shoji K; Bradley JS; Reed MD; van den Anker JN; Domonoske C; Capparelli EV
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2150-6. PubMed ID: 26810655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.
    Hanberg P; Öbrink-Hansen K; Thorsted A; Bue M; Tøttrup M; Friberg LE; Hardlei TF; Søballe K; Gjedsted J
    Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29530848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cefepime Dosing in Neonates: What is the Evidence?
    McDonald D; Shah P
    Am J Perinatol; 2021 Jun; 38(7):657-661. PubMed ID: 31777048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of Individualized Cefepime Dosing Strategy Using Population Pharmacokinetics.
    Mo Y; Shcherbakova N; Inman KL; Li WK; Kovalenko K; Rosenberg J; Orsini J; Truong J
    J Clin Pharmacol; 2022 Mar; 62(3):359-365. PubMed ID: 34542174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.